Trials / Completed
CompletedNCT05536440
A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine PF-07261271 for the potential treatment of Inflammatory Bowel Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07261271 | IV or SC |
| DRUG | Placebo | IV or SC |
Timeline
- Start date
- 2022-10-17
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2022-09-10
- Last updated
- 2025-03-24
- Results posted
- 2025-03-24
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05536440. Inclusion in this directory is not an endorsement.